Wednesday, November 11, 2026
Explore

Explore the substrate

Search everything we hold — entities, source-backed facts, the conclusions we’re drawing, and the sources behind them. Type a topic, not just a claim. How we source →

15 items across the substrate for “Fed policy”

What we're concluding

1
narrative· bearish

10-Year Treasury Yield Hits 5% as Fed Faces Intensifying Oversight

The 10-year Treasury yield surged to 5%, its highest level since 2007, marking a sharp tightening of financial conditions that raises borrowing costs across the economy and pressures rate-sensitive equities, including high-multiple AI and fintech names. The move coincides with a dense cycle of Federal Reserve congressional testimony spanning monetary policy, bank supervision, and financial innovation, signaling heightened scrutiny of how the central bank is managing the tightening cycle and its spillover into technology-driven finance.

Jerome PowellMary BarraMax P. BowmanAndrew Gibson

Source-backed facts

6

policy_rate_cut_probability: 80 percent

Yahoo Finance ↗· 25 Nov 2025

fed_funds_rate: 3.75 percent (Q1 2026)

Yahoo Finance ↗· 19 Apr 2026

inflation_target: 2 percent (Q3 2026)

Fool ↗· 14 Sep 2026

fed_funds_rate: 4 percent (Q2 2026)

Yahoo Finance ↗· 17 Apr 2026

policy_rate: 3.50-3.75 percentsources differ

Seeking Alpha ↗· 1 Feb 2026

neutral_fed_funds_rate: 3.25 percent

Yahoo Finance ↗· 26 Jan 2026

Sources we've traced

8
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com